<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586820</url>
  </required_header>
  <id_info>
    <org_study_id>859-05</org_study_id>
    <nct_id>NCT00586820</nct_id>
  </id_info>
  <brief_title>Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI</brief_title>
  <acronym>BQ-123</acronym>
  <official_title>Role of Endothelin in Microvascular Dysfunction Following Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous coronary intervention (PCI) for acute coronary syndromes frequently fails to
      restore myocardial perfusion despite establishing epicardial vessel patency. Endothelin-1
      (ET-1) is a potent vasoconstrictor and its expression is increased in atherosclerotic
      coronary arteries. Our hypothesis is that increased activity of the endogenous endothelin
      system contributes to microvascular dysfunction, and adjunctive therapy with an endothelin
      receptor antagonist will result in improved microvascular blood flow.

      Aims: The aims of the study are to assess in patients with non ST-elevation myocardial
      infarction, whether: 1) PCI causes an increase in coronary blood ET-1 level; 2) an endothelin
      receptor antagonist acutely improves coronary microvascular blood flow following PCI.

      Non-ST segment elevation myocardial infarction (NSTEMI) is one type of heart attack. It is
      defined as the development of heart muscle necrosis results from an acute interruption of
      blood supply to a part of the heart which is demonstrated by an elevation of cardiac markers
      Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) in the blood and the absence of
      ST-segment elevation in ECG (electrocardiography). ST-segment is a portion of ECG, its
      elevation indicates full thickness damage of heart muscle. Absence of ST-segment elevation in
      NSTEMI indicates partial thickness damage of heart muscle occurs. Therefore, NSTEMI is less
      severe type of heart attack compared to STEMI (ST-segment elevation myocardial infarction) in
      which full thickness damage of heart muscle occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our hypothesis is that the endogenous endothelin system contributes to microvascular
      dysfunction and impaired myocardial reperfusion following successful PCI for non ST-elevation
      MI, and that endothelin receptor antagonism will improve microvascular flow. The study will
      provide new insight into the humoral regulation of the microcirculation in patients
      presenting with acute coronary syndromes.

      General methods: This section describes our approach to investigating the specific aims. The
      study is a prospective, double blind, placebo-controlled trial to assess the efficacy of a
      selective endothelin type A receptor antagonist (BQ-123), as adjunctive therapy for PCI for
      non ST elevation MI. The control group will receive placebo rather than another vasodilator
      in order to specifically elucidate the role of the endogenous endothelin system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI)</measure>
    <time_frame>immediately following PCI procedure</time_frame>
    <description>Coronary microvascular blood flow will be assessed following successful PCI by measuring APV in the culprit vessel using Doppler echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI</measure>
    <time_frame>immediately pre-PCI, 8 hours post-PCI, 16 hours post-PCI</time_frame>
    <description>CK-MB is a cardiac marker that can demonstrate the development of heart muscle necrosis resulting from an acute interruption of blood supply to a part of the heart. CK-MB is measured by a blood test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Myocardial Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ-123</intervention_name>
    <description>BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
    <arm_group_label>BQ-123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Clinical diagnosis of unstable angina or non ST-elevation myocardial infarction, and
             requiring clinically indicated PCI for the management of non ST elevation acute
             coronary syndrome.

        Exclusion Criteria:

          -  Systemic hypotension (systolic &lt;90 mmHg)

          -  Heart failure or known ejection fraction &lt; 30%

          -  Left main disease

          -  Culprit lesion is in a saphenous vein graft

          -  100% occlusion of the culprit vessel or culprit is an ostial right coronary stenosis

          -  Currently enrolled in other active cardiovascular investigational studies

          -  Severe endocrine, hepatic, or renal disorders

          -  Pregnancy or lactation

          -  Federal Medical Center inmates

          -  Inability or unwillingness to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhiram Prasad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <results_first_submitted>April 21, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amir Lerman</investigator_full_name>
    <investigator_title>Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Coronary Atherosclerosis</keyword>
  <keyword>Microvascular Dysfunction</keyword>
  <keyword>Non-ST Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BQ-123</title>
          <description>The selective endothelin type A receptor antagonist (BQ-123) will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsuccessful PCI</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>12 subjects were enrolled on the BQ-123 arm, but 1 subject was excluded due to unsuccessful PCI.</population>
      <group_list>
        <group group_id="B1">
          <title>BQ-123</title>
          <description>BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="11.2"/>
                    <measurement group_id="B2" value="64" spread="12.5"/>
                    <measurement group_id="B3" value="64.27" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI)</title>
        <description>Coronary microvascular blood flow will be assessed following successful PCI by measuring APV in the culprit vessel using Doppler echocardiography.</description>
        <time_frame>immediately following PCI procedure</time_frame>
        <population>One subject on the BQ-123 arm was excluded from the analysis due to unsuccessful PCI.</population>
        <group_list>
          <group group_id="O1">
            <title>BQ-123</title>
            <description>BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI)</title>
          <description>Coronary microvascular blood flow will be assessed following successful PCI by measuring APV in the culprit vessel using Doppler echocardiography.</description>
          <population>One subject on the BQ-123 arm was excluded from the analysis due to unsuccessful PCI.</population>
          <units>cm/s</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="20" upper_limit="37"/>
                    <measurement group_id="O2" value="19" lower_limit="9" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI</title>
        <description>CK-MB is a cardiac marker that can demonstrate the development of heart muscle necrosis resulting from an acute interruption of blood supply to a part of the heart. CK-MB is measured by a blood test.</description>
        <time_frame>immediately pre-PCI, 8 hours post-PCI, 16 hours post-PCI</time_frame>
        <population>One subject on the BQ-123 arm was excluded from the analysis due to unsuccessful PCI.</population>
        <group_list>
          <group group_id="O1">
            <title>BQ-123</title>
            <description>BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Creatinine Kinase Isoenzyme Muscle/Brain Type (CK-MB) From Immediately Pre-PCI to 8 and 16 Hours Post-PCI</title>
          <description>CK-MB is a cardiac marker that can demonstrate the development of heart muscle necrosis resulting from an acute interruption of blood supply to a part of the heart. CK-MB is measured by a blood test.</description>
          <population>One subject on the BQ-123 arm was excluded from the analysis due to unsuccessful PCI.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Change immediate pre-PCI, 8 hr post-PCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" lower_limit="-26" upper_limit="-10"/>
                    <measurement group_id="O2" value="26" lower_limit="-15" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change immediate pre-PCI, 16 hr post-PCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" lower_limit="-38" upper_limit="14"/>
                    <measurement group_id="O2" value="107" lower_limit="2" upper_limit="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change between the groups from immediate pre-PCI and 8 hours post PCI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change between the groups from immediate pre-PCI and 16 hours post-PCI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BQ-123</title>
          <description>BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects randomized to the placebo arm will receive a placebo infusion for 20 minutes prior to PCI.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amir Lerman</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-6670</phone>
      <email>lerman.amir@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

